shot-button
Subscription Subscription
Home > Sports News > Cricket News > Article > Yuvraj Singh diagnosed with Grade I cancer

Yuvraj Singh diagnosed with Grade I cancer

Updated on: 06 February,2012 10:33 AM IST  | 
ANI |

Cricket all-rounder Yuvraj Singh has been diagnosed with Grade I cancer and is currently undergoing chemotherapy in the United States

Yuvraj Singh diagnosed with Grade I cancer

Cricket all-rounder Yuvraj Singh has been diagnosed with Grade I cancer and is currently undergoing chemotherapy in the United States.

A tumour on his lung was diagnosed as non-malignant late last year, but his physiotherapist, Dr Jatin Chaudhary, said it was cancerous but "100% curable".


He said that he expected Yuvraj to be fit to play by May this year. "It is a rare tumour and is cancerous but it has been detected in stage 1 itself (Stage 0 refers to cancer that is just beginning, while stages 1 to 4 are progressively more advanced cancers)," Dr. Chaudhary said.


"Doctors had to decide whether to continue medication or go for chemotherapy but since parts of the tumour are just above the artery of his heart, there was a danger that while running it could burst.


But it is 100 percent curable. "The doctors decided that he would have to undergo chemotherapy and he travelled to the US on January 26. End of March, he would undergo a CT scan and should recover by then," Dr. Chaudhary said.

Yuvraj hasn't played competitive cricket since the Tests against West Indies last November, when news of his tumour became public.

He had originally hoped to make a comeback in the tri-series in Australia, but last month it was announced that he would not be fit in time for the IPL, which begins in April.

"Exciting news! Mid-day is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest news!" Click here!


Mid-Day Web Stories

Mid-Day Web Stories

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK